<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487316</url>
  </required_header>
  <id_info>
    <org_study_id>PKU-2015052005</org_study_id>
    <nct_id>NCT02487316</nct_id>
  </id_info>
  <brief_title>A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib</brief_title>
  <official_title>A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospitals affiliated to the China PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Air Force General Hospital of the PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of crizotinib combined with
      CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALK(+) Systemic Anaplastic Large Cell Lymphoma patients are treated with crizotinib when they
      receive CHOP chemotherapy. crizotinib 250mg twice a day is administrated from day 1 of
      chemotherapy to 18 weeks. standard CHOP chemotherapy (cyclophosphamide, 750mg per square
      meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area,
      maximal dose is 2mg d1, doxorubicin, 50mg per square meter of body-surface area d1, plus
      prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of &gt;/Grade 3 non-hematology toxicity adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL assessment</measure>
    <time_frame>2 years</time_frame>
    <description>using a battery of cognitive and quality-of-life (QoL) measures</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Systemic Anaplastic Large-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>crizotinib combined with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.</description>
    <arm_group_label>crizotinib combined with chemotherapy</arm_group_label>
    <other_name>CHOP chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary ALK(+) systemic anaplastic large cell lymphoma histologically confirmed by
             biopsy without therapy

          -  ECOG 0-2

          -  more than 1 measurable lesions with major axis &gt;1.5cm and minor axis&gt;1.0cm

          -  estimated survival &gt;/3months

          -  Age 18-65 years

          -  Women of childbearing age should have a negative pregnancy test; men and women who
             need to agree to use effective contraception during the period of treatment and the
             following 1 years

          -  Signature of informed consent

        Exclusion Criteria:

          -  Age &lt;\ 18years

          -  without ALK(+) systemic anaplastic large cell lymphoma histologically confirmed by
             biopsy

          -  without measurable lesions

          -  being treated by other drugs in other clinical trials

          -  Pregnant or lactating women, who are not willing to take contraceptive measures during
             the study period, or are not willing to use effective contraceptive measures during
             the period of treatment and the following 1 years

          -  Hepatic insufficiency: serum total bilirubin, ALT more than 2 times higher than normal

          -  Renal insufficiency: more than 2 times higher than that of normal serum creatinine

          -  Blood screening period: WBC &lt; 1 * 109/L * 109/L; platelet &lt; 25; Hb &lt; 60g/L

          -  HIV test positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weiping Liu</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. Br J Haematol. 2015 Mar;168(6):771-83. doi: 10.1111/bjh.13265. Epub 2015 Jan 6. Review.</citation>
    <PMID>25559471</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Department of Hematology Oncology, clinical oncology college, Director of department, Party Secretary</investigator_title>
  </responsible_party>
  <keyword>Anaplastic Large Cell Lymphoma</keyword>
  <keyword>anaplastic lymphoma kinase rearrangement</keyword>
  <keyword>crizotinib</keyword>
  <keyword>CHOP chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

